Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PEG-asparaginase.

Cecilia H Fu1, Kathleen M Sakamoto

  • 1Childrens Hospital Los Angeles, Division of Hematology/Oncology, Los Angeles, CA, USA.

Expert Opinion on Pharmacotherapy
|August 19, 2007
PubMed
Summary
This summary is machine-generated.

PEG-asparaginase offers a safer and more effective treatment for acute leukemias by reducing hypersensitivity reactions. This modified enzyme, L-asparaginase linked to polyethylene glycol, is crucial in current leukemia therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
Same author

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.

Leukemia·2026
Same author

Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia.

Cancer research·2026
Same author

DHODH as a targetable metabolic Achilles' heel for chemotherapy-resistant B-ALL.

Blood·2026
Same author

Inflammatory pathways and the bone marrow microenvironment in inherited bone marrow failure syndromes.

Stem cells (Dayton, Ohio)·2025
Same author

Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

bioRxiv : the preprint server for biology·2025
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • L-asparaginases are vital in acute leukemia treatment, acting by depleting essential asparagine.
  • Hypersensitivity reactions and antibody development limit traditional L-asparaginase efficacy.
  • PEG-asparaginase was developed to mitigate immunogenicity and extend half-life.

Purpose of the Study:

  • To evaluate the clinical significance of PEG-asparaginase in acute lymphoblastic leukemia.
  • To assess the feasibility of alternative administration routes for PEG-asparaginase.

Main Methods:

  • Review of clinical trials and studies on PEG-asparaginase.
  • Analysis of efficacy and safety data for intramuscular administration.
  • Evaluation of ongoing research into intravenous PEG-asparaginase.

Related Experiment Videos

Main Results:

  • Intramuscular PEG-asparaginase is established in frontline pediatric and adult acute lymphoblastic leukemia therapy.
  • PEG-asparaginase demonstrates reduced immunogenicity and prolonged half-life compared to native L-asparaginase.
  • Current research focuses on the viability of intravenous administration.

Conclusions:

  • PEG-asparaginase represents a significant advancement in leukemia treatment, improving patient outcomes.
  • The modified enzyme overcomes key limitations of conventional L-asparaginases.
  • Further investigation into intravenous administration may expand therapeutic options.